Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2026 07:00 ET | Source: Sitryx Therapeutics

First-in-Class Oral PKM2 Modulator SYX-5219 Phase 1a Trial Data to be Presented at SID 2026

First-in-human healthy volunteers trial showed SYX-5219 was safe and well toleratedSystemic immunomodulation of type 2 inflammation demonstrated with reduction in serum CCL17/TARC Phase 1b trial in...
May 06, 2026 16:01 ET | Source: Journey Medical Corporation

Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

SCOTTSDALE, Ariz., May 06, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on...
April 28, 2026 12:02 ET | Source: Quoin Pharmaceuticals, Inc.

CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs

Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications. Company to Initiate Investigator Led Clinical Study in Pachyonychia...
April 28, 2026 08:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs

Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications. Company to Initiate Investigator Led Clinical Study in Pachyonychia...
April 21, 2026 08:30 ET | Source: Journey Medical Corporation

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

SCOTTSDALE, Ariz., April 21, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company...
April 15, 2026 02:18 ET | Source: Clinuvel Pharmaceuticals Limited

CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026

MELBOURNE, Australia, April 15, 2026 (GLOBE NEWSWIRE) -- CLINUVEL’s innovative photomedicine and vitiligo programs featured extensively at the recent American Academy of Dermatology (AAD) Annual...
April 13, 2026 13:21 ET | Source: BCC Research LLC

Dermatology Devices Market to Reach $25.6 Billion by 2030, Driven by Rising Skin Cancer Incidence and Aesthetic Demand

Market growth is fueled by growing awareness of skin health, technological innovation, and expanding applications in both medical and cosmetic dermatology.
March 31, 2026 15:44 ET | Source: Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome

Inhibitor Therapeutics (OTCQB: INTI) updates itraconazole PK study, highlights amorphous formulation and planned global patent filing.
March 28, 2026 15:00 ET | Source: Biogen Inc.

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving...
March 28, 2026 13:30 ET | Source: Alumis Inc.

Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

Envudeucitinib late-breaking data at AAD: early and robust improvements in skin clearance, quality of life and psoriasis symptoms in two Phase 3 trials